Karlijn Hummelink

Chapter 1 General introduction and thesis outline	9
Outline of this thesis	16
Part 1 PD-1T TILs as precision and clinical applicable biomarker in NSCLC	23
Chapter 2 PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC	25
Supplemental Material	57
Chapter 3 Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non small cell lung cancer	81
Supplemental material	107
Chapter 4 A dysfunctional T cell gene signature for predicting non response to PD‑1 blockade in non-small cell lung cancer that is suitable for routine clinical diagnostics	129
Supplemental material	153
Part 2 Serum and pleural effusion as bio-sources for diagnostic biomarker tests	169
Chapter 5 A serum protein classifier identifying patients with advanced non-small cell lung cancer who derive clinical benefit from treatment with immune checkpoint inhibitors	171
Supplemental material	194
Chapter 6 Cell-free DNA in the supernatant of pleural effusion can detect driver and resistance mutations and can guide TKI treatment decisions	211
Supplemental material	222
Part 3 Summary and future perspectives	231
Chapter 7 Summary and future perspectives	233
Chapter 8 Nederlandse samenvatting	251
Appendices	261
Chapter 5 Supplemental material: Methods	263
Chapter 2 Commentary by Anagnostou V and Luke JJ in Clinical Cancer Research	279
List of publications	287
Curriculum Vitae	293
Dankwoord	297

Made with FlippingBook

RkJQdWJsaXNoZXIy MTk4NDMw